Preterm infants 32 weeks postmenstrual age or older:0
10 mg/kg/dose IV every 6 hours as needed or around-the-clock:0
May consider a 20 mg/kg loading dose:0
20 to 25 mg/kg orally:0
then 12 to 15 mg/kg/dose every 12 hours as needed or around-the-clock:0
30 mg/kg rectally:0
then 12 to 18 mg/kg/dose every 12 hours as needed or around-the-clock:0
Administer IV over 15 minutes:0
dose should be administered within 6 hours:0
The administered volume in a neonate should always be 7.5 mL or less:0
the odds ratio (OR) was 1.6 (95% CI, 1.48 to 1.74) for the risk of asthma in children among users of acetaminophen in the year prior to asthma diagnosis and the first year of life:0
and 1.96 (95% CI, 1.5 to 2.56) for the risk of wheezing and acetaminophen use in the previous year of life:0
In 2 observationa studies, the OR was 3.61 (95% CI, 1.33 to 9.77) for atopy and acetaminophen exposure before the age of 15 months:0
and up to 2.39 (95% CI, 2.24 to 2.55) for rhinoconjunctivitis symptoms or 1.99 (95% CI, 1.82 to 2.16) for eczema symptoms and acetaminophen exposure in the previous 12 months in adolescents:0
Peak serum concentration occurs approximately 60 minutes after an oral dose:1
Elimination half-life is approximately 3 hours in term neonates:0
5 hours in preterm neonates greater than 32 weeks gestation, and up to 11 hours in more immature neonates:0
A 20 mg/kg loading dose achieved a Cmax of 15 to 25 mg/L in 19 neonates (27 to 42 weeks gestational age) included in the PARANEO study:0
An effect compartment concentration of 10 mg/L was associated with a pain score reduction of 3.4 units:1
A mean plasma concentration of 11 mg/L after acetaminophen IV 10 mg/kg every 6 hours:1
Elimination half-life is approximately 3 hours in term neonates:0
5 hours in preterm neonates greater than 32 weeks gestation:0
A 20 mg/kg loading dose achieved a Cmax of 15 to 25 mg/L in 19 neonates (27 to 42 weeks gestational age) included in the PARANEO study:0
An effect compartment concentration of 10 mg/L was associated with a pain score reduction of 3.4 units:1
A mean plasma concentration of 11 mg/L after acetaminophen IV 10 mg/kg every 6 hours:1
(with or without a 20 mg/kg loading dose) was predicted from a pharmacokinetic analysis of 158 neonates (28 to 44 weeks gestation):0
Target concentrations above 10 mg/L are predicted in 50% of patients administered acetaminophen (30 mg/kg orally loading dose):1
15 mg/kg/dose orally every 8 hours and 37.5 mg/kg rectally loading dose:0
20 mg/kg/dose every 8 hours) in a population pharmacokinetic analysis (n=30, 1 to 90 days old, 31 to 40 weeks gestational age):0
Injection site events (pain and site reactions 15%) and vomiting (5%) occur with IV acetaminophen:0
Hypothermia did not develop in 99 neonates (93 normothermic and 6 with fever) administered IV acetaminophen:0
Hepatotoxicity occurred in less than 0.01% of children administered therapeutic doses of acetaminophen, in a systemic review (n=32,424 studies=62):0
The estimated risk for minor or major hepatic events was 0.031% (95% CI, 0.015% to 0.057%):0
No significant increases in liver enzymes were observed after a median duration of 60 hours (6 to 480 hours) and a median of 9 (2 to 80) doses of IV acetaminophen (20 mg/kg loading dose):0
10 mg/kg (every 6 hours for more than 36 weeks postmenstrual age (PMA):0
every 8 hours for 31 to 36 weeks PMA:0
and every 12 hours for less than 31  weeks postmenstrual age) in 189 infants (1 day to 182 days of age; 30 to 55 weeks PMA):0
Suppositories contain 80,120, 325, and 650 mg:0
Intravenous formulation available in a 100-mL glass vial containing 1000 mg (10 mg/mL):0
150 mg/kg in 5% dextrose or 1/2 NS given IV over 60 minutes (loading dose):0
followed by 50 mg/kg in 5% dextrose or 1/2 NS over 4 hours:0
then 100 mg/kg in 5% dextrose or 1/2 NS over 16 hours:0
NAC solution concentrations of 40 mg/mL have been used to avoid fluid overload and hyponatremia in the neonate:1
Acetaminophen 10 mg/mL:0
Cimetidine 12 mg/mL:0
dextrose 5% in lactated Ringer solution:0
dextrose 5% in normal saline:0
dextrose 10%:0
dexamethasone 10 mg/mL:0
diphenhydramine 50 mg/mL:0
dolasetron 20 mg/mL:0
fentanyl 50 mcg/mL:0
granisetron 0.1 mg/mL:0
heparin 100 units/mL:0
hydrocortisone 50 mg/mL:0
hydromorphone 4 mg/mL:0
ketorolac 15 mg/mL:0
lorazepam 0.5 mg/mL:0
methylprednisolone 125 mg/mL:0
metoclopramide 5 mg/mL:0
morphine 15 mg/mL:0
nalbuphine 20 mg/m:0
ondansetron 2 mg/mL:0
slowly mix in 20 mL of 1% methylcellulose, and then add in 20 mL of simple syrup to make a total volume of 40 mL:0
and then add in 20 mL of simple syrup to make a total volume of 40 mL:0
For infusion, dilute appropriate dose in sufficient volume of D5W or NS to final concentration of 0.8 mg/mL:1
The volume of distribution, half-life, clearance, and peak concentration were 4.67 L/kg, 453 minutes:1
to decrease oxidation, then adding sufficient water to make a final volume of 200 mL:0
Captopril oral suspension can be made by dissolving 6.25 mg (one-half of a scored 12.5-mg tablet) in 10 mL of sterile water, adding 1000 mg of sodium ascorbate for injection (4 mL of 250-mg/mL solution) to decrease oxidation, then adding sufficient water to make a final volume of 200 mL:0
and adding enough Simple Syrup, NF, for a final volume of 60 mL:0
adding 2 mL of Purified Water:0
USP, to make a fine paste, and adding enough Simple Syrup, NF, for a final volume of 60 mL:0
Mix 30 mL of 800 mcg/mL solution using dobutamine concentration of 12.5 mg/mL:1
0.8 mg/mL:0
800 mcg/mL:0
12.5 mg/mL:0
1.9 mL of dobutamine:0
Add 1.9 mL of dobutamine (12.5 mg/mL) to 28.1 mL of compatible solution (eg, D5W) to yield 30 mL of infusion solution with a concentration of 800 mcg/mL:1
1.9 mL of dobutamine:0
Supplied as 250 mg per 20-mL vial (12.5 mg/mL) and premixed bags in concentrations of 1, 2, and 4 mg/mL:1
A 0.5 mg/mL oral suspension can be made by diluting 1 mL of the 4 mg/mL IV solution up to a total volume of 8 mL with a mixture of Ora-Sweet® and Ora-Plus:0
0.075 mg/kg/dose every 12 hours for 3 days:0
A 0.5 mg/mL oral suspension can be made by diluting 1 mL of the 4 mg/mL IV solution up to a total volume of 8 mL with a mixture of Ora-Sweet® and Ora-Plu:0
Available as 50% concentrated solution in 50-mL single-dose vials and syringes, and 25% concentrated solution in single-use 10-mL syringes:0
a  dilution of the 100 mcg/mL concentration to provide a final concentration of 10 mcg/mL may be required:1
For small dose volumes, a dilution of the 100 mcg/mL concentration to provide a final concentration of 10 mcg/mL may be required:1
May dilute the reconstituted solution with NS to a concentration of 1 mg/mL for small doses or to an appropriate volume of NS for administration:1
Mix 50 mL of 20 mcg/mL solution using epinephrine concentration of 1 mg/mL:1
0.02 mg/mL:0
Add 1 mL of epinephrine  to 49 mL of compatible solution (eg, D5W) to yield 50 mL of infusion solution with a concentration of 20 mcg/mL:1
To prepare a 20 mg/mL dilution of the oral suspension:0
dilute 5 mL of the 200 mg/5 mL (40 mg/mL) erythromycin ethylsuccinate suspension (suspension made from powder for suspension only) up to a final volume of 10 mL with sterile water:0
To prepare a 20 mg/mL dilution of the oral suspension:0
dilute 5 mL of the 200 mg/5 mL (40 mg/mL) erythromycin ethylsuccinate suspension (suspension made from powder for suspension only) up to a final volume of 10 mL with sterile wa:0
Wide variability in apparent volume of distribution (10 to 30 L/kg) and serum half-life (1 to 15 hours):0
then add to this mixture enough vehicle to make a final volume of 120 mL:0
mixture of Ora-Sweet (or Ora-Sweet SF) and Ora-Plus or cherry syrup) to make a final volume of 100 mL:0
to make a final volume of 60 mL:0
Add enough Oral-Sweet to make a final volume of 200 mL:0
Add vehicle to almost volume, transfer to amber bottle and add vehicle to final volume of 120 mL:0
Supplied as a 10-mg/mL sterile solution for injection in 2-mL single use vials:0
A recent study found that 20 mL of priming volume was sufficient to minimize adsorption losses for a 1 unit/mL insulin infusion:0
Mix 50 mL of 2400 mcg/mL solution using lidocaine:0
then adding cherry syrup to make a total volume of 83 mL:0
Reconstitute 1-g vial with 3.4 mL of sterile water for injection to provide a final volume of 4 mL and a concentration of 250 mg/mL:1
Volume of distribution of approximately 0.5 L/kg in infants and children:0
A 2-mg/mL concentration can be prepared by reconstituting up to a total volume of 10 mL with water:1
Determine dose and total volume required for compounding. For a dose of 15 mg or less, total volume is 37.5 mL:0
total volume is 100 mL:0
total volume is 125 mL:0
115 mL for 10 capsules (total volume, 125 mL):0
137 mL for 12 capsules (total volume, 150 mL):0
To prepare a 1 mg/mL solution, dilute 1 mL of the 10 mg/mL solution up to a final volume of 10 mL with NS:0
Transfer contents of the mortar to the calibrated bottle and add enough vehicle to bring the total volume to 120 mL:0
Pour the remaining contents into the amber glass bottle, then add enough simple syrup to make the final volume 120 mL:0
then add enough simple syrup to make the final volume 120 mL:0
The administered volume in a neonate should always be 7.5 mL or less:0
Use 110% of the internal lumen volume of the catheter, not to exceed 2 mg in 2 mL:0
and then add in 20 mL of simple syrup to make a total volume of 40 mL:0
20 mL:0
100 mL:0
5 mL:0
10 mL:0
100 mL:0
crush a 200-mg tablet, slowly mix in 20 mL of 1% methylcellulose:0
and then add in 20 mL of simple syrup to make a total volume of 40 mL:0
available as 1.5 mg/mL (150 mg/100 mL) and 1.8 mg/mL (360 mg/200 mL) concentrations in premix bags:1
and then add in 20 mL of simple syrup to make a total volume of 40 mL:0
Reconstitute with 10 mL of D5W or preservative free sterile water to a concentration of 5 mg/mL:1
Reconstitute with 10 mL of D5W:0
Available as a suspension containing 100-mg Abelcet in 20-mL (5 mg/mL):0
Reconstitute by adding 12 mL of sterile water for injection to a yield a concentration of 4 mg/mL:1
filter) 1 mL of reconstituted solution into 3 mL of D5W:1
Reconstitute 50-mg and 100-mg vials with 15 mL and 30 mL:0
10 mg/kg/dose IV every 6 hours as needed or around-the-clock:0
May consider a 20 mg/kg loading dose:0
7.5 mg/kg/dose IV every 6 hours (maximum 30 mg/kg/24 hours) as needed or around the clock for pain or fever:0
20 to 25 mg/kg orally:0
then 12 to 15 mg/kg/dose every 12 hours as needed or around-the-clock:0
then 12 to 15 mg/kg/dose every 6 hours as needed or around-the-clock: 0
30 mg/kg rectally:0
then 12 to 18 mg/kg/dose every 12 hours as needed or around-the-clock:0
A 20 mg/kg loading dose achieved a Cmax of 15 to 25 mg/L in 19 neonates (27 to 42 weeks gestational age) included in the PARANEO study:0
An effect compartment concentration of 10 mg/L was associated with a pain score reduction of 3.4 units:1
A mean plasma concentration of 11 mg/L after acetaminophen IV 10 mg/kg every 6 hours (with or without a 20 mg/kg loading dose) was predicted from a pharmacokinetic analysis of 158 neonates (28 to 44 weeks gestation): 1
No significant increases in liver enzymes were observed after a median duration of 60 hours (6 to 480 hours) and a median of 9 (2 to 80) doses of IV acetaminophen (20 mg/kg loading dose):0
10 mg/kg (every 6 hours for more than 36 weeks postmenstrual age (PMA), every 8 hours for 31 to 36 weeks PMA, and every 12 hours for less than 31 weeks postmenstrual age) in 189 infants (1 day to 182 days of age30 to 55 weeks PMA), in a retrospective analysis:0
Available orally in various liquid formulations containing 32, 80, and 100 mg/mL:1
Suppositories contain 80,120, 325, and 650 mg:0
Intravenous formulation available in a 100-mL glass vial containing 1000 mg (10 mg/mL):0
150 mg/kg in 5% dextrose or 1/2 NS given IV over 60 minutes (loading dose):0
then 100 mg/kg in 5% dextrose or 1/2 NS over 16 hours:0
NAC solution concentrations of 40 mg/mL have been used to avoid fluid overload and hyponatremia in the neonate:1
Acetaminophen 10 mg/mL:0
Cimetidine 12 mg/mL:0
dexamethasone 10 mg/mL:0
diphenhydramine 50 mg/mL:0
dolasetron 20 mg/mL:0
fentanyl 50 mcg/mL:0
granisetron 0.1 mg/mL:0
heparin 100 units/mL:0
hydrocortisone 50 mg/mL:0
hydromorphone 4 mg/mL:0
ketorolac 15 mg/mL:0
lidocaine 20 mg/mL:0
lorazepam 0.5 mg/mL:0
mannitol 150 mg/mL (15%):0
methylprednisolone 125 mg/mL:0
metoclopramide 5 mg/mL:0
midazolam 5 mg/mL:0
morphine 15 mg/mL:0
nalbuphine 20 mg/mL:0
ondansetron 2 mg/mL:0
potassium chloride 0.1 mEq/mL:0
10 mg/kg/dose IV every 6 hours as needed or around-the-clock:0
Available orally in various liquid formulations containing 32, 80, and 100 mg/mL:0
Suppositories contain 80,120, 325, and 650 mg:0
Vial is for single use only and should be used within 6 hours of opening:0
Compatibility information refers to physical compatibility and is derived from Trissel’s™ 2 Clinical Pharmaceutics Database:0
Risk of transient renal dysfunction and crystalluria is minimized by slow infusion rates and adequate patient hydration:0
Reconstituted solution is stable at room temperature for 12 hours:0
==Solution Compatibility== D5W and NS:0
Proventil® HFA and Ventolin® HFA 90 mcg albuterol base per actuation:0
10 mg/kg/dose IV every 6 hours as needed or around-the-clock: 0
May consider a 20 mg/kg loading dose:0
7.5 mg/kg/dose IV every 6 hours (maximum 30 mg/kg/24 hours) as needed or around the clock for pain or fever:0
20 to 25 mg/kg orally:0
then 12 to 15 mg/kg/dose every 12 hours as needed or around-the-clock:0
then 12 to 15 mg/kg/dose every 6 hours as needed or around-the-clock: 0
30 mg/kg rectally:0
then 12 to 18 mg/kg/dose every 12 hours as needed or around-the-clock:0
A 20 mg/kg loading dose achieved a Cmax of 15 to 25 mg/L in 19 neonates (27 to 42 weeks gestational age) included in the PARANEO study:0
An effect compartment concentration of 10 mg/L was associated with a pain score reduction of 3.4 units:1
A mean plasma concentration of 11 mg/L after acetaminophen IV 10 mg/kg every 6 hours (with or without a 20 mg/kg loading dose) was predicted from a pharmacokinetic analysis of 158 neonates (28 to 44 weeks gestation): 1
No significant increases in liver enzymes were observed after a median duration of 60 hours (6 to 480 hours) and a median of 9 (2 to 80) doses of IV acetaminophen (20 mg/kg loading dose):0
10 mg/kg (every 6 hours for more than 36 weeks postmenstrual age (PMA), every 8 hours for 31 to 36 weeks PMA, and every 12 hours for less than 31 weeks postmenstrual age) in 189 infants (1 day to 182 days of age; 30 to 55 weeks PMA), in a retrospective analysis:0
Available orally in various liquid formulations containing 32, 80, and 100 mg/mL:0
Suppositories contain 80,120, 325, and 650 mg:0
Intravenous formulation available in a 100-mL glass vial containing 1000 mg (10 mg/mL):0
150 mg/kg in 5% dextrose or 1/2 NS given IV over 60 minutes (loading dose):0
then 100 mg/kg in 5% dextrose or 1/2 NS over 16 hours:0
NAC solution concentrations of 40 mg/mL have been used to avoid fluid overload and hyponatremia in the neonate:1
Acetaminophen 10 mg/mL:0
Cimetidine 12 mg/mL:0
dexamethasone 10 mg/mL:0
diphenhydramine 50 mg/mL:0
dolasetron 20 mg/mL:0
fentanyl 50 mcg/mL:0
granisetron 0.1 mg/mL:0
heparin 100 units/mL:0
hydrocortisone 50 mg/mL:0
hydromorphone 4 mg/mL:0
ketorolac 15 mg/mL:0
lidocaine 20 mg/mL:0
lorazepam 0.5 mg/mL:0
mannitol 150 mg/mL (15%):0
methylprednisolone 125 mg/mL:0
metoclopramide 5 mg/mL:0
midazolam 5 mg/mL:0
morphine 15 mg/mL:0
nalbuphine 20 mg/mL:0
ondansetron 2 mg/mL:0
potassium chloride 0.1 mEq/mL:0
For IM injection, use a concentration of 225 mg/mL. Maximum 330 mg/mL:1
Reconstitute 500-mg vial using 2 mL of sterile water for injection to a concentration of 225 mg/mL:1
Reconstitute 1000-mg vial using 3 mL of sterile water for injection to a concentration of 330 mg/mL:1
Reconstitute 1000-mg vial using 3 mL of sterile water for injection to a concentration of 330 mg/mL:1
For IM injection, use a concentration of 225 mg/mL:1
Reconstitute 500-mg vial using 2 mL of sterile water for injection to a concentration of 225 mg/mL:1
Reconstitute 1000-mg vial using 3 mL of sterile water for injection to a concentration of 330 mg/mL:1
Give as an intermittent IV infusion at a concentration of 10 to 40 mg/mL over 15 to 60 minutes:1
Reconstitute 1-g vial with 9.5 mL sterile water for injection to aconcentration of 100 mg/mL:1
Reconstitute 500-mg vial with 10 mL of sterile water for injection to make a concentration of 50 mg/mL:1
10 mg/kg/dose IV every 6 hours as needed or around-the-clock:0
Available orally in various liquid formulations containing 32, 80, and 100 mg/mL:0
Suppositories contain 80,120, 325, and 650 mg:0
Intravenous formulation available in a 100-mL glass vial containing 1000 mg (10 mg/mL):0
150 mg/kg in 5% dextrose or 1/2 NS given IV over 60 minutes (loading dose), followed by 50 mg/kg in 5% dextrose or 1/2 NS over 4 hours, then 100 mg/kg in 5% dextrose or 1/2 NS over 16 hours:0
NAC solution concentrations of 40 mg/mL have been used to avoid fluid overload and hyponatremia in the neonate:1
0.01 to 0.05 mg/kg/dose orally every 8 to 12 hours:0
Available in 12.5-mg, 25-mg, 50-mg, and 100-mg tablets:0
Captopril oral suspension can be made by dissolving 6.25 mg (one-half of a scored 12.5-mg tablet) in 10 mL of sterile water, adding 1000 mg of sodium ascorbate for injection (4 mL of 250-mg/mL solution) to decrease oxidation, then adding sufficient water to make a final volume of 200 mL:0
The final concentration is 0.03 mg/mL captopril and 5 mg/mL sodium ascorbate:1
Dissolve one 200-mg tablet in 2.5-mL of water for a concentration of 80 mg/mL for oral or nasogastric (NG) tube administration:1
Doses used in these cases ranged from 70 to 200 mg/kg/day, administered as a single dose or over a 48-hour period:0
Available as a 200-mg tablet:0
Initial, 100 to 250 mg/kg/day divided into 2 to 4 doses per day concomitantly with other ammonia lowering agents:0
Based on retrospective case series (n=22), maintenance doses were typically less than 100 mg/kg/day:0
Dissolve one 200-mg tablet in 2.5-mL of water for a concentration of 80 mg/mL for oral or nasogastric (NG) tube administration:1
Doses used in these cases ranged from 70 to 200 mg/kg/day:0
25 mg/m2 (or approximately 2 mg/kg) per dose every 24 hours:0
Administer by slow IV infusion over approximately 1 hour at a concentration not to exceed 0.5 mg/mL:1
Cancidas is supplied as a white to off-white powder cake in single-use vials, containing either 50 or 70 mg:0
To prepare the 50-mg (5 mg/mL) or 70-mg (7 mg/mL) Cancidas® vial:0
to a final concentration not to exceed 0.5 mg/mL:1
Maximum 330 mg/mL:0
Available as powder for injection in 500-mg and 1000-mg vials:0
Reconstitute 500-mg:0
vial using 2 mL of sterile water for injection to a concentration of 225 mg/mL:1
Reconstitute 1000-mg vial using 3 mL of sterile water for injection to a concentration of 330 mg/mL:1
further dilute reconstituted drug to a concentration of 5 to 20 mg/mL in compatible solution:1
inject slowly over 3 to 5 minutes at a concentration of 100 mg/mL:1
For IM injection, use a concentration of 225 mg/mL:1
Maximum 330 mg/mL:0
Available as powder for injection in 500-mg and 1000-mg vials:0
Reconstitute 500-mg vial using 2 mL of sterile water for injection to a concentration of 225 mg/mL:1
Reconstitute 1000-mg vial using 3 mL of sterile water for injection to a concentration of 330 mg/mL:1
Available as powder for injection in 1-g and 2-g vials:0
Reconstitute 1-g vial with 9.5 mL sterile water for injection to a concentration of 100 mg/mL:1
90 to 100 mg/kg/day IV divided every 8 hours:0
Give as an intermittent IV infusion at a concentration of 10 to 40 mg/mL over 15 to 60 minutes:1
Available as powder for injection in 500-mg and 1-g, 2-g, and 6-g vials:0
Reconstitute 500-mg vial with 10 mL of sterile water for injection to make a concentration of 50 mg/mL:1
Prepared by reconstituting 500-mg vial with 2.2 mL of 1% lidocaine without epinephrine or Sterile Water to a concentration of 200 mg/mL:1
25 to 50 mg/kg (maximum 125 mg) IV/IM as a single dose:0
In all cases,the ceftriaxone dose (150 to 200 mg/kg/day) significantly exceeded the FDA recommended dose and/or was administered IV push:0
Available as a powder for injection in 250-mg, 500-mg, 1-g, and 2-g vials:0
Prepared by reconstituting powder with compatible solution (sterile water for injection, D5W, or D10W) to a concentration of 100 mg/mL:1
To make 40-mg/mL solution add 6.2 mL to the 250-mg vial:0
Prepared by reconstituting 250-mg vial with 0.9 mL of 1% lidocaine without epinephrine to a concentration of 250 mg/mL:1
20 mg/kg IV every 8 hours:0
When reconstituted with NS to a final concentration between 2.5 to 50 mg/mL:1
Solutions prepared in D5W at concentrations of 1 to 20 mg/mL are stable in plastic syringes for up to 6 hours when refrigerated:0
Inject a 0.5-mg/mL solution of phentolamine subcutaneously into the affected area:0
Increase as needed to maximum of 3.5 mg/kg per dose every 6 hours:0
0.25 mg/kg per dose every 6 hours:0
0.01 mg/kg every 6 hours over 10 minutes:0
Increase as needed to maximum of 0.15 mg/kg per dose every 6 hours:0
Usual maintenance doses have been 2 to 3 mg/kg/day orally in 3 divided doses:0
Initial doses of 2 mg/kg/day orally in 3 divided doses have been used while some authors recommend starting at 0.3 to 1 mg/kg/day to assess tolerability and then increasing to 2 mg/kg/day incrementally over several days:0
Supplied in multiple concentrations (0.05-, 0.1-,0.4-, and 1-mg/mL) for injection:1
Reconstitute 300mg bottle with 9 mL of water to provide a final concentration of 100 mg per 5 mL (20 mg/mL):1
The concentration of the reconstitute solution is 100 mg/mL:1
Dilute prior to administration using a compatible solution to a final concentration of 1 to 2 mg/mL:1
Reconstitute 300 mg bottle with 9 mL of water to provide a final concentration of 100 mg per 5 mL (20 mg/mL):1
The concentration of the reconstituted solution is 100 mg/mL:1
In most cases, this has followed use of the 0.75% concentration:1
The volume of distribution, half-life, clearance, and peak concentration were 4.67 L/kg, 453 minutes, 7.9 mL/kg/min, and 0.52 mcg/mL, respectively, in 8 very low birthweight:1
otal and free bupivacaine concentrations were 0.31+/-0.17 mcg/mL and 0.047+/-0.032 mcg/mL:1
Therapeutic trough serum concentration is 5 to 25 mcg/mL:1
Concentrations greater than 40 to 50 mcg/mL are toxic:1
of caffeine anhydrous powder in 250 mL of water, yielding a final concentration of 10 mg/mL:1
Therapeutic trough serum concentration is 5 to 25 mcg/mL:1
Alternatively, an oral solution may be prepared by dissolving 2.5 g of caffeine anhydrous powder in 250 mL of water, yielding a final concentration of 10 mg/mL:1
defined as a serum ionized calcium concentration less than approximately 4 mg/dL:1
serum ionized calcium concentration less than approximately 4 mg/dL:1
Dissolve one 200-mg tablet in 2.5-mL of water for a concentration of 80 mg/mL for oral or nasogastric:1
Do NOT administer tablets whole or crushed. Dissolve one 200-mg tablet in 2.5-mL of water for a concentration of 80 mg/mL:1
Administer by slow IV infusion over approximately 1 hour at a concentration not to exceed 0.5 mg/mL:1
compatible solution (NS, ½ NS, ¼ NS, LR) to a final concentration not to exceed 0.5 mg/mL:1
Administer by slow IV infusion over approximately 1 hour at a concentration not to exceed 0.5 mg/mL:1
Remove desired volume of drug based on calculated dose and further dilute in compatible solution (NS,½ NS, ¼ NS, LR) to a final concentration not to exceed 0.5 mg/mL:1
For IV bolus injection, inject slowly over 3 to 5 minutes at a concentration of 100 mg/mL:1